by LBCA Steering Committee member Diane Mapes (aka @double_whammied) Report from ASCO 2019:Â Q & A with Dr. Otto Metzger The 2019 annual meeting of the […]
Interview: Study highlights differences in Pre-menopausal ILC/IDC Read More »
Study indicates oncoplastic and shave margin surgical techniques for ILC mastectomies reduce repeated surgeries for lobular breast cancer (ILC)
Study: Beneficial Surgical Techniques for ILC Lumpectomies Read More »
The ROLO trial is a targeted therapy clinical trial in the United Kingdom for patients with advanced or metastatic lobular breast cancer. Name of the
ROLO: Targeted Therapy Trial for Advanced ILC Read More »
The Lobular Breast Cancer Alliance (@LobularBCA) made its Twitter debut on a special #BCSM Tweetchat “Understanding Lobular Breast Cancer” on August 13, 2018. The tweets
#BCSM Tweetchat: Freaky, Sneaky ILC Read More »
The GELATO clinical trial was a lobular breast-cancer specific immunotherapy trial investigating the response to an immunotherapy + chemotherapy medication combination. This phase 2 trial
GELATO: Immunotherapy Clinical Trial for ILC Mets Read More »
The 2018 Northwest Metastatic and Lobular Breast Cancer Conference (NWMBCC) was held October 26th and 27th in Seattle WA. It included three patient-oriented educational sessions
ILC Recorded Educational Sessions – NWMBCC 2018 Read More »
Women who have been diagnosed with Stage 1 – 3 invasive lobular breast cancer (ILC) who have not yet had surgery to remove their tumor may be eligible to participate in a clinical trial. This trial is open to all ER+ and/or PR+ HER2- patients (ductal or lobular), however it is being enriched with lobular breast cancer patients to promote a better understanding of how ILC might respond differently to these therapies.
PELOPS: Clinical Trial with Palbociclib for Pre-surgical ILC Patients Read More »
Lobular Breast Cancer (ILC) and the Lobular Breast Cancer Alliance (LBCA) will be featured on the final day of Harvard Medical School’s annual comprehensive educational course Breast Cancer: New Horizons, Current Controversies July 12 – 14, 2018 at the Boston Marriott Long Wharf. Advocate Registration to attend the course is open.
Materials Available: Boston 2018 ILC Course Read More »
Excerpt below. Read the full article from the Fred Hutch News Service or Download and Share a printable .pdf. Lobular breast cancer comes into the spotlight
IN THE NEWS: Lobular Breast Cancer Comes into the Spotlight Read More »
Learn how Lobular Breast Cancer is a different disease and understand clinical considerations for treating ILC.
After Breast Cancer Diagnosis (ABCD) Webinar: All Breast Cancer Isn’t Alike … Read More »
The European School of Oncology (ESO) offered an e-learning session on November 10, 2018 focusing on treatment of early-stage lobular breast cancer. The session entitled Treatment of
European School of Oncology: Treatment for early stage ILC Read More »
Patient advocates identify opportunities to improve patient outcomes and care
Lobular Breast Cancer Alliance Inc. (LBCA) is a Delaware nonprofit corporation that is registered as a 501(c)(3) public charity. Tax ID Number: 86-2260246. Donations to LBCA are tax-deductible. to the fullest extent allowed by applicable law.
© 2024 The Lobular Breast Cancer Alliance Inc. | Privacy Policy | Terms of Use | State Fundraising Notices
Site by SuzanneHarrisonWeb.com